Insmed is a biopharmaceutical company. Co.'s product, ARIKAYCE, is approved as ARIKAYCE® (amikacin liposome inhalation suspension) for the treatment of Mycobacterium avium complex lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. Co.'s pipelines include: brensocatib, an oral reversible inhibitor of dipeptidyl peptidase 1 for the treatment of patients with bronchiectasis and other neutrophil-mediated diseases; and treprostinil palmitil inhalation powder, an inhaled formulation of the treprostinil prodrug treprostinil palmitil for pulmonary arterial hypertension and other rare pulmonary disorders. The INSM stock yearly return is shown above.
The yearly return on the INSM stock yearly return page and across the coverage universe of our site,
is a measure of the annual return over the calendar year 2015 for the given stock.
When performing this calculation it is important to factor in dividends, because a financial instrument's annual return is
more than just the change in price if that instrument pays a dividend or coupon.
One way to factor dividends into the return is simply to count them as cash — we don't do
that here. Instead, our website aims to empower investors
by performing the INSM annual return calculation with any dividends reinvested as applicable (on ex-dates).
|